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Edited by Felix WielandAbstract Wolfram syndrome is caused by mutations in WFS1
encoding wolframin, a polytopic membrane protein of the endo-
plasmic reticulum. Here, we investigated the molecular patho-
mechanisms of four missense and two truncating mutations in
WFS1. Expression in COS-7 cells as well as direct analysis of
patient cells revealed that WFS1 mutations lead to drastically
reduced steady-state levels of wolframin. All mutations resulted
in highly unstable proteins which were delivered to proteasomal
degradation. No wolframin aggregates were found in patient
cells suggesting that Wolfram syndrome is not a disease of pro-
tein aggregation. Rather, WFS1 mutations cause loss-of-func-
tion by cellular depletion of wolframin.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Wolfram syndrome is a rare autosomal-recessive disorder
deﬁned by the association of early-onset diabetes mellitus
and optic atrophy. Additional neurological and endocrinolog-
ical manifestations may be present [1]. The disease phenotype
is caused by mutations in WFS1 on 4p16 [2,3] encoding the
100 kDa protein wolframin. Secondary structure analysis pre-
dicted wolframin as a multispanning membrane protein with
nine transmembrane segments [3]. Wolframin is a resident
component of the endoplasmic reticulum (ER) [4] with an
Ncyt/Clum orientation in the ER membrane [5]. Recent studies
suggested an involvement in the regulation of ER stress [6–8].
To date, a wide spectrum of diﬀerent mutations in WFS1 is
known to cause Wolfram syndrome [9]. Most of them repre-
sent inactivating mutations implying that they cause a loss-
of-function phenotype. Consistently, our previous study and
that of others showed lack of wolframin in ﬁbroblasts derived
from patients with genotypes W371X/R629W, fs343X396/
fs343X396 [5] or G695V/W648X [7]. However, there is no cur-
rent concept about how wolframin is inactivated. We proposed
that instability of WFS1 transcripts is associated with truncat-
ing mutations W371X and F343fsX396, whereas mutation*Corresponding author. Fax: +49 89 3081733.
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co-authors [7] suggested that missense mutations G695V and
P724L cause inactivation by formation of wolframin aggre-
gates. Here, we investigated the eﬀects of six diﬀerent missense
mutations and truncating mutations on the expression level,
stability, degradation and the intracellular fate of wolframin.
We show that all theseWFS1 mutations result in unstable pro-
teins. Proteasomal degradation but not formation of aggre-
gates contributes to cellular depletion of wolframin.2. Materials and methods
2.1. Generation of WFS1 constructs
Wolframin mutants were generated by the megaprimer mutagenesis
protocol. A mutated megaprimer was ampliﬁed using an outside
wild-type (WT) primer (forward or reverse) and a middle mutagenic
primer (forward or reverse). This megaprimer was used in a second
round of PCR together with the appropriate outside primer. Mutants
F883X and P885L were generated by a single PCR step. Human
WFS1 in pIRES2 [5] was used as template for PCR. Primers were:
WT-F, 50-atggactccaacactgctccg-30; WT-R, 50-tcaggccgccgacaggaatc-30;
P504L-R, 5 0-catagagcaggcacaggacgctg-3 0; R629W-F, 5 0-ctgacgtggagc-
tccatgg-30; W700X-R, 5 0-gaagcggccggtctacgtg-30; P724L-F, 50-catcaaca-
tgctcctgttcttcatc-3 0; F883X-R, 5 0-tcagaaaaagaagtcgaagcc-30; P885L-R,
5 0-tcaggccgccgacaggaataggaagaa-3 0. A high ﬁdelity Taq polymerase
(Roche) was used for all PCR ampliﬁcations. WFS1 fragments were
ligated into pIRES2 (Clontech) and sequenced using an automated
ABI310 sequencer.2.2. Cell culture and transfection
Fibroblasts derived from a healthy individual as well as from
Wolfram syndrome patients carrying mutations W371X/R629W,
fs343X396/fs343X396 [5] or W700X/W700X were used in this study.
Fibroblasts and COS-7 cells were cultured at 37 C in DMEM supple-
mented with 10% fetal calf serum (FCS) and 2 mM glutamine. COS-7
cells were transfected with WFS1 constructs in 12-well tissue culture
plates using Metafectene (Biontex). Twenty-four hours post-transfec-
tion, cells were either used for metabolic labelling experiments or har-
vested by trypsinisation. When indicated, cells were grown in the
presence of lactacystin (Calbiochem) or E-64 (Sigma).2.3. Pulse-chase experiments
Pulse-chase experiments were performed as described previously [5].
In brief, construct-transfected COS-7 cells were pulse-labeled for 30
min with 100 lCi/ml 35S-labeled methionine/cysteine (NEN) and then
chased for indicated time periods. At each time point, cells were lysed
in IP buﬀer (20 mMHEPES pH 7.4, 150 mMNaCl, 10% glycerol) con-
taining 1% SDS and protease inhibitors (mini complete, Roche) for
30 min at 0 C. Cleared extracts were subjected to immunoprecipita-
tion with anti-WoN antibody bound to Protein A-sepharose and ana-
lysed by SDS/PAGE (3–8% NuPage Tris–acetate gels, Invitrogen) and
autoradiography.blished by Elsevier B.V. All rights reserved.
Fig. 1. Steady-state levels of mutated and truncated forms of
wolframin. (A) Construct-transfected COS-7 cells were lysed in SDS
buﬀer and analysed by immunoblotting with anti Wo-N. (B) Immu-
noblot analysis of control ﬁbroblasts and of two patients (W371X/
R629W, W700X/W700X). Aliquots (5 · 104 cells) were resolved by
SDS/PAGE and blotted with anti-WoN and anti-b actin.
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Fibroblasts were grown until sub-conﬂuency and then ﬁxed in ice-
cold methanol (100%) for 20 min. Blocking was done in 1 · PBS
containing milk powder (5%) followed by incubation with anti-WoN
(1:100) in blocking solution for 90 min at room temperature.
Incubation with secondary antibody was performed for 60 min using
anti-rabbit IgG-FITC (1:360, Sigma). Slides were mounted in ﬂuores-
cent mounting medium (DAKO), sealed and then analysed in a confo-
cal microscope with the appropriate ﬁlter.
2.5. Detergent extraction
Transfected COS-7 cells (1 · 105 cells) were lysed in 100 ll
1 · PBS pH 7.4, 10% glycerin, 2 mM EDTA, 1% Nonidet P-40
(Sigma) and protease inhibitors (mini complete, Roche) for 30 min
on ice. Insoluble material was recovered by centrifugation at
20000 · g for 15 min and solubilised in 50 ll 10 mM Tris/HCl pH
7.4, 1% SDS for 10 min at room temperature. After addition of
200 ll detergent buﬀer, samples were sonicated for 20 s. TCA-precip-
itated proteins derived from soluble and insoluble fractions were
then separated on 7% Tris–acetate gels (Invitrogen) and analysed
by immunoblotting.
2.6. RT-PCR analysis
RNA from cultured ﬁbroblasts was extracted using TRIZOL (Invit-
rogen) and treated with DNAse (Promega) according to the manufac-
tures recommendations. First-strand cDNA was synthesised from total
RNA using oligo (d)T primers and Superscript II (Invitrogen). RT-
PCR ampliﬁcation was performed with human WFS1-speciﬁc prim-
ers (F: 5 0-cctgccactgcgtctgaag-30; R: 5 0-ccacatccaggttgggctc-30) and
GAPDH-speciﬁc primers (F: 5 0-gtccactggcgtcttcacca-30; R: 5 0-ggtgg-
cagtgatggcatggac-3 0) and analysed after diﬀerent cycle numbers. The
WFS1 primers used here amplify a region of the gene which spans
an intron; the GAPDH primers correspond to published primers for
pseudogene-free ampliﬁcation of the GAPDH gene [10].Fig. 2. Semi-quantitative RT-PCR analysis of WFS1. First-strand
cDNAs derived from two patients (W700X/W700X, fs343X396/
fs343X396) and a control were analysed by PCR using WFS1- or
GAPDH-speciﬁc primers as a control. PCR products corresponding to
26 cycles are shown.3. Results
3.1. WFS1 mutations
In this study, we investigated four missense and two truncat-
ing WFS1 mutations. The missense mutations correspond to
sequence portions encoding transmembrane helical (P504L),
cytoplasmic loop (R629W) and lumenal C-terminal (P724L,
P885L) domains of wolframin. Of these, P504L, R629W and
P885L belong to the known rare homozygous missense muta-
tions [2,11,12]. The W700X mutation represents a novel inac-
tivating mutation present in homozygosity in a female
patient. It leads to truncation of a major portion of the hydro-
philic C-terminus. The F883X mutation causes deletion of the
last eight amino acid residues and mimics a group of frame-
shift mutations aﬀecting the very C-terminus of wolframin
[2,11,13].
3.2. WFS1 mutations lead to cellular depletion of wolframin
To assess steady-state concentrations of wolframin mutants,
we used transient expression of wild-type and mutated con-
structs in COS-7 cells. Cells expressing the wild-type wolframin
showed very strong signals at about 100 kDa (Fig. 1A). In con-
trast, the steady-state concentrations of mutants were signiﬁ-
cantly reduced when compared to the wild-type protein. The
direct analysis of endogenous mutated wolframin in patient
cells revealed a more drastic reduction (Fig. 1B): signals corre-
sponding to wolframinW700X were almost undetectable in
respective patient cells and wolframinR629W was markedly re-
duced compared to control cells. We conclude that WFS1
mutations, both truncating and missense mutations, cause
cellular depletion of wolframin.3.3. Truncating mutations of WFS1 are associated with stable
transcripts
Nonsense and frameshift mutations generate premature stop
codons which may cause mRNA degradation through non-
sense-mediated mRNA decay (NMD) and thus, absence of
the encoded protein [14]. We asked whether late truncating
mutations W700X and F883X cause instability of WFS1 tran-
scripts. Since reliable RT-PCR analysis of construct-transfec-
ted cells is hampered by residual plasmid DNA, we directly
determined levels ofWFS1 transcripts in W700X/W700X ﬁbro-
blasts. For comparison, we re-analysed patient ﬁbroblasts with
F343fsX396 present in homozygosity [5]. RT-PCR analysis re-
vealed stableWFS1 transcripts in W700X/W700X cells (Fig. 2).
Surprisingly, we also obtained stable WFS1 transcripts in
F343fsX396/F343fsX396 ﬁbroblasts what was in contrast to
our previous ﬁndings [5]. False-positive results due to ampliﬁ-
cation from residual genomic DNA could be excluded. We
speculate that the interference of pseudogene sequences by
the use of diﬀerent GAPDH primers in the former study has
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conclude that WFS1 mutations carrying premature stops
downstream of F343fsX396 encode stable transcripts.
3.4. Missense and truncating mutations in WFS1 reduce the
stability of wolframin
The WFS1 mutations investigated here may result in unsta-
ble proteins as shown previously for the R629W mutation [5].
To determine possible diﬀerences in protein stability between
wild-type and mutant wolframin, we performed pulse-chase
experiments using construct-transfected COS-7 cells. As shown
in Fig. 3, wild-type wolframin was stable over a chase period of
6 h and reduced to about 50% after 24 h. In contrast, the
amounts of wolframin mutants decreased more rapidly. Mu-
tants P504L and P724L were decreased to about 50% after a
chase period of 6 h whereas mutants R629W, P885L, W700X
and F883X were almost reduced to background levels after
this chase period. This demonstrates that WFS1 mutations,
at least those investigated here, result in unstable wolframin
proteins which exhibit markedly reduced half-lives.Fig. 4. Degradation of wolframin by the proteasome. (A) Construct-
transfected COS-7 cells were treated with lactacystin (50 lM) or
solvent (DMSO) only for 16 h. Cells were harvested and analysed by
immunoblotting. (B) Fibroblasts derived from two patients (W371X/
R629W, W700X/W700X) and a control were treated with either
lactacystin (50 lM) or E-64 (10 lM) for 2 days and then analysed by
immunoblotting.3.5. Wolframin mutants are degraded by the proteasome
Many mutated proteins are delivered to the proteasomal
pathway for rapid degradation. We asked whether proteaso-
mal degradation is responsible for low concentrations of wolfr-
amin mutants. Therefore, the eﬀect of the proteasome inhibitor
lactacystin on steady-state levels of wolframin was assessed.
Levels of wild-type wolframin were only slightly increased
whereas a marked accumulation of the mutants P504L,
R629W, P724L and P885L was observed in the presence of
the inhibitor (Fig. 4A). The increase of mutants W700X and
F883X was less pronounced although signiﬁcant. These data
indicate that degradation of wolframin mutants transiently ex-
pressed in COS-7 is mediated by the proteasome pathway.
To analyse degradation mechanisms of endogeneous
mutants, ﬁbroblasts from two patients (W371X/R629W,Fig. 3. Stability of wild-type and mutant wolframin. Construct-
transfected COS-7 cells were radiolabeled with 35S-cysteine/methionine
and analysed after the indicated time periods (chase) by immunopre-
cipitation followed by SDS/PAGE and autoradiography.W700X/W700X) and a control were treated with either lactacy-
stin or E-64, an inhibitor of cysteine proteases. In the presence
of lactacystin, we observed a marked increase of wolfr-
aminR629W (Fig. 4B). WolframinW371X and wolframinW700X
which were almost undetectable in untreated ﬁbroblasts, accu-
mulated to signiﬁcant levels. The inhibitor E-64 had almost no
eﬀect on wolframin levels in patient cells (Fig. 4B). We con-
clude that the cellular depletion of wolframin in patient cells
is essentially caused by proteasomal degradation.
3.6. Aggregate formation does not contribute to loss-of-function
of wolframin
A recent study suggested that mutation P724L leads to the
formation of detergent-insoluble aggregates of wolframin when
expressed in COS-7 cells [7]. We asked whether also other
WFS1mutations induce aggregation of wolframin. Such aggre-
gates may escape detection by direct analysis of cell lysates. To
investigate possible diﬀerences in detergent extractability of
wild-type versus mutant wolframin, construct-transfected
COS-7 cells were solubilised and then separated by centrifuga-
tion into detergent-soluble (supernatant) and detergent-insolu-
ble (pellet) fractions. Whereas wild-type wolframin was found
exclusively in the supernatant fraction, mutations R629W,
W700X and F883X signiﬁcantly increased the levels of insolu-
ble forms of the protein (Fig. 5A) suggesting conversion into
Fig. 5. The fate of mutated wolframin. Either (A) construct-transfec-
ted COS-7 cells or (B) patient ﬁbroblasts were fractionated into
detergent-insoluble pellet (P) and detergent-soluble supernatant (S)
fractions and analysed by immunoblotting. A longer exposition time
was required to visualise endogeneous mutants. (C) Immunoﬂuore-
sence analysis of wolframin of control and patient ﬁbroblasts. A
reticular pattern of staining was found with control ﬁbroblasts whereas
patient ﬁbroblasts showed very weak staining.
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detected in the detergent-soluble fraction.
It cannot be excluded that the aggregate formation is related
to the system of transient expression in COS-7 cells. We, there-
fore, investigated the fate of endogeneous wolframin mutants
in patient cells. As shown in Fig. 5B, wolframinR629W and
wolframinW700X were entirely released into the supernatant
fraction similar to wild-type wolframin. Immunoﬂuorescence
studies conﬁrmed that formation of aggregates is not involved
in loss-of-function of wolframin in patients (Fig. 5C). Whereas
control cells showed a strong and reticular pattern of staining
with anti-WoN, only background staining was found with pa-
tients cells with no signs of punctuate-like staining. We con-
clude that conversion of mutant forms of wolframin to
insoluble aggregates is not the leading pathomechanism in
patient cells. Rather, mutated proteins appear to be rapidly
degraded at an early stage of biogenesis.4. Discussion
We show that mutations causing Wolfram syndrome are
associated with cellular depletion of wolframin irrespective ofwhether the mutations encode full-length or truncated pro-
teins. Transient expression of constructs carrying missense
mutations or C-terminal deletions revealed reduced steady-
state levels compared to wild-type wolframin. In agreement
with this ﬁnding, wolframin is also absent in patient cells: in
a newly identiﬁed patient with mutation W700X present in
homozygosity, in a patient carrying W371X/R629W [5] and
a further patient with mutations G695S/W648X [7] conﬁrming
that depletion of wolframin is underlying the disease.
All mutations investigated here obviously encode stable
transcripts. We demonstrated stable W700X transcripts in a
patient indicating that a premature stop at this position does
not trigger NMD. Most likely, this is also true for downstream
mutations like F883X. Re-investigation of a mutation generat-
ing a premature stop upstream of W700X, F343fsX396, also
revealed stable WFS1 transcripts. This is in line with the rule
that a premature stop must lie 50–55 nucleotides upstream of
the last exon–exon junction to trigger NMD [15]. According
to this rule, only mutations generating premature stops up-
stream of position 269 within wolframin should cause NMD.
This applies to a minority of known WFS1 mutations.
Pulse-chase experiments indicated that reduced half lives of
wolframin mutants were responsible for low protein levels sug-
gesting an increased degradation of wolframin mutants. In-
deed, in the presence of lactacystin, transiently expressed
wolframin mutants were stabilised. Similarly, treatment of
W371X/R629W patient cells with lactacystin led to accumula-
tion of wolframinR629W to almost wild-type levels. Thus, sim-
ilar to other mutated proteins, wolframin is target of ER
quality control [16]. Notably, most of the mutants were not re-
stored to wild-type levels in the presence of lactacystin. It can-
not be excluded that non-proteasomal mechanisms contribute
to degradation of wolframin mutants. Furthermore, proteo-
lytic fragments generated by N-terminal cleavage may escape
detection by antibody anti-WoN.
In an increasing number of neurodegenerative disorders the
pathophysiology is directly related to the deposition of aggre-
gates of mutated proteins [17,18]. Indeed, when transiently ex-
pressed, mutants R629W, W700X and F883X partially formed
insoluble aggregates. Thus, the probability of aggregate forma-
tion appears to be directly related to distinct amino acid substi-
tutions or to the deletion of C-terminal amino acids causing
changes in properties such as charges, secondary structure pro-
pensities or hydrophobicity. Our ﬁnding that transiently ex-
pressed P724L is nearly completely soluble is diﬀerent from
the study by Fonseca et al. [7] indicating that other inﬂuences
like conditions of overexpression may additionally aﬀect the
fate of wolframin mutants. Nevertheless, our data provide evi-
dence that formation of wolframin aggregates is not of major
relevance in patient cells. We found endogeneous wolframin
mutants exclusively in the detergent-soluble fraction. Indirect
immunoﬂuorescence studies supported these ﬁndings.
Our ﬁndings suggest that Wolfram syndrome is not a disease
of protein aggregation. It is unlikely that the mutant proteins
themselves contribute considerably to the neuronal degenera-
tion in patients through a toxic gain of function. Rather,
WFS1 mutations lead to loss of normal cellular function by
rapid degradation and cellular depletion of wolframin.Acknowledgements: We thank B. Treske and E. Wagner for excellent
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